healthcare

Telix Pharmaceuticals has just reported its first year of positive operating cashflow... helping it to achieve NPAT.

The rapid pace of change in biotechnology is creating a golden age of innovation - and three experts share what they are watching.

CSL has delivered bumper returns once again in its half-year report but suffered a major setback this week.

There are two parts of the market we believe are setting up for strong returns in 2024: Small caps and Healthcare.

The medtech landscape is rife with fast growing companies typically operating in oligopolistic industry structures that drive profitability.

The collapse of China chatter seems overcooked. The China A-share market now looks like a screaming buy, so I list my Crazy-Eight top picks.

Below is a summary of the topics we covered on Nucleus Investment Insights this month. See the links for more information.

In this interview, KKR's Richard Schoenfeld outlines where he is seeing stress in the market today.

Morningstar has released its Q4 2023 guide to undervalued stocks and there’s a few big hitters in the mix.

Miracle weight loss drugs are providing opportunity in the Healthcare sector, and its not Novo-Nordisk